173 related articles for article (PubMed ID: 21606492)
1. Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
Cochran BJ; Croucher DR; Lobov S; Saunders DN; Ranson M
J Biol Chem; 2011 Jul; 286(27):24467-75. PubMed ID: 21606492
[TBL] [Abstract][Full Text] [Related]
2. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
3. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
[TBL] [Abstract][Full Text] [Related]
5. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
Lee JA; Croucher DR; Ranson M
Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
[TBL] [Abstract][Full Text] [Related]
6. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
7. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
Croucher DR; Saunders DN; Stillfried GE; Ranson M
Biochem J; 2007 Dec; 408(2):203-10. PubMed ID: 17696882
[TBL] [Abstract][Full Text] [Related]
8. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Westrick RJ; Røjkjaer LP; Yang AY; Roh MH; Siebert AE; Ginsburg D
J Thromb Haemost; 2020 Nov; 18(11):2968-2975. PubMed ID: 32780555
[TBL] [Abstract][Full Text] [Related]
10. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
11. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.
Cochran BJ; Gunawardhana LP; Vine KL; Lee JA; Lobov S; Ranson M
BMC Biotechnol; 2009 May; 9():43. PubMed ID: 19442270
[TBL] [Abstract][Full Text] [Related]
12. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
13. SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.
Schroder WA; Hirata TD; Le TT; Gardner J; Boyle GM; Ellis J; Nakayama E; Pathirana D; Nakaya HI; Suhrbier A
Sci Rep; 2019 Aug; 9(1):12421. PubMed ID: 31455834
[TBL] [Abstract][Full Text] [Related]
14. Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Rushworth LK; Kidger AM; Delavaine L; Stewart G; van Schelven S; Davidson J; Bryant CJ; Caddye E; East P; Caunt CJ; Keyse SM
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18267-72. PubMed ID: 25489104
[TBL] [Abstract][Full Text] [Related]
15. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
16. TNFα-Erk1/2 signaling pathway-regulated SerpinE1 and SerpinB2 are involved in lipopolysaccharide-induced porcine granulosa cell proliferation.
Qu X; Guo S; Yan L; Zhu H; Li H; Shi Z
Cell Signal; 2020 Sep; 73():109702. PubMed ID: 32619562
[TBL] [Abstract][Full Text] [Related]
17. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
18. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
Schroder WA; Major LD; Le TT; Gardner J; Sweet MJ; Janciauskiene S; Suhrbier A
Cancer Med; 2014 Jun; 3(3):500-13. PubMed ID: 24644264
[TBL] [Abstract][Full Text] [Related]
20. microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.
Jin T; Suk Kim H; Ki Choi S; Hye Hwang E; Woo J; Suk Ryu H; Kim K; Moon A; Kyung Moon W
Oncotarget; 2017 May; 8(20):32769-32782. PubMed ID: 28427146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
